These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16021360)

  • 1. The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis.
    Sormani MP; Bruzzi P; Beckmann K; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Wagner K; Filippi M
    J Neurol; 2005 Dec; 252(12):1455-8. PubMed ID: 16021360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H; Miller A; Paty D; Weinshenker B;
    Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b.
    Sormani MP; Bruzzi P; Beckmann K; Wagner K; Miller DH; Kappos L; Filippi M;
    Neurology; 2003 May; 60(9):1462-6. PubMed ID: 12743232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
    Barkhof F; Polman CH; Radue EW; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Poppe P; de Vos M; Lasri F; Bauer L; Dahms S; Wagner K; Pohl C; Sandbrink R
    Arch Neurol; 2007 Sep; 64(9):1292-8. PubMed ID: 17846268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
    Zhao GJ; Koopmans RA; Li DK; Bedell L; Paty DW
    Neurology; 2000 Jan; 54(1):200-6. PubMed ID: 10636148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
    Molyneux PD; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker GJ; Thompson AJ; Miller DH
    Brain; 2000 Nov; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
    Inglese M; van Waesberghe JH; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Yousry TA; Wagner K; Comi G; Filippi M
    Neurology; 2003 Mar; 60(5):853-60. PubMed ID: 12629246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
    Kappos L; Polman C; Pozzilli C; Thompson A; Beckmann K; Dahlke F;
    Neurology; 2001 Dec; 57(11):1969-75. PubMed ID: 11739811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.